SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dicerna Pharmaceuticals, Inc. - DRNA

NEW YORK, June 10, 2015 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dicerna Pharmaceuticals, Inc. ("Dicerna" or the "Company") DRNA.  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Dicerna and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. 

On June 10, 2015, Seeking Alpha website published a report which stated that "Alnylam Pharmaceuticals ALNY files a lawsuit in Massachusetts against Dicerna Pharmaceuticals accusing it of misappropriating trade secrets Alnylam acquired via its buyout of Sirna Therapeutics from Merck in January 2014.

The suit accuses Dicerna of obtaining its trade secrets by hiring six scientists from Merck who were involved in RNAi work, despite each of them signing a confidentiality agreement. It alleges that Dicerna's subsequent product candidates and delivery technologies are 'strikingly similar' to Sirna's/Merck's. It also alleges that certain scientists hired by Dicerna were seen taking material out of the Merck facility prior to their departure."

On this news, shares of Dicerna fell $0.88 per share, to $15.22, or more than 5.47%, in after-hours trading on June 10, 2015.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-dicerna-pharmaceuticals-inc--drna-300097479.html

SOURCE Pomerantz LLP